Back to Agenda
Session 5: NB Update: EU MDR Article 117 Current Impact to Drug Delivery Devices
Session Chair(s)
Kirsten H. Paulson, MS, RAC
Pfizer, Inc., United States
With less than a year until the EU MDR is effective, many questions remain on how combination products will be affected. This session will discuss late-breaking information on the impact of Article 117 and how companies are preparing.
Learning Objective : At the conclusion of this session, the participant should be able to:- Analyze regulatory expectations and industry challenges in complying with Article 117
- Discuss considerations for prioritizing portfolio remediation
- Discuss the latest information from EMA and Notified Bodies
Speaker(s)
NB Update: EU MDR Article 117 Current Impact to Drug Delivery Devices
Ibim B. Tariah, PhD
Regulatory & Quality Solutions (R&Q), United States
Vice President, EU MDR & IVDR Services
Have an account?